APW
FDMT icon

Aventura Private Wealth’s 4D Molecular Therapeutics FDMT Stock Holding History

Aventura Private Wealth’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110
Closed -$355 – 799
2025
Q1 		$355 Hold
110
– – ﹤0.01% 738
2024
Q4 		$613 Buy
+110
New +$863 ﹤0.01% 674

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aventura Private Wealth's FDMT Position: Q2 2025 in Review

Aventura Private Wealth sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 110 shares — an estimated $355 sold.

Aventura Private Wealth first reported a position in FDMT in Q4 2024 and held it in 2 quarters. The position peaked at $613 in Q4 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Aventura Private Wealth reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aventura Private Wealth sold 110 4D Molecular Therapeutics shares in Q2 2025, an estimated $355.
  • Aventura Private Wealth first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 2 quarters.
  • Aventura Private Wealth's 4D Molecular Therapeutics position peaked at $613 in Q4 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Aventura Private Wealth's 13F filing for Q2 2025, filed 7 Jan 2026.